Loading…
Danish pharmaceutical company specializing in allergy immunotherapy tablets and injections.
Danish pharmaceutical company specializing in allergy immunotherapy tablets and injections.
Patients take the tablets or injections for several years, so revenue builds from a base of ongoing treatments and reflects reimbursement rules in each country. Europe is the core, with the US a smaller but growing market. The Lundbeck Foundation, a Danish charitable holding, is the main shareholder.
Moat: narrow (IP / patents, regulatory licence, process know-how). One of few global specialists in allergy immunotherapy with approvals across many markets.
Headquarters: Horsholm, Denmark · Founded: 1923 · Employees: 2,721
Size ALK-abello A/S (ALK-B.CO) is a Denmark Health Care company (Pharmaceuticals: Major) with a market value of $8.14B, the 16th largest of 59 Denmark companies the cockpit tracks. Shares closed at DKK 242.80 on 6 Nov 2026.
Performance Over six months the shares fell 5.0%, against +14.2% for the median peer and +8.8% for the Denmark market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue grew 16.5% over the last twelve months (peer median +12.8%); the operating margin is 26.7% (peer median 13.8%).
Valuation It trades at 35.7× forward earnings against a peer median of 23.4× (4th most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -5 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 19.3 points above its cost of capital (5.9% WACC).
Next results Next results expected around 17 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | DKK 6.83B | DKK 6.31B | DKK 5.54B | DKK 4.82B | DKK 4.51B |
| Revenue growth | — | +14% | +15% | +7% | — |
| Gross profit | DKK 4.65B | DKK 4.16B | DKK 3.47B | DKK 2.95B | DKK 2.72B |
| EBITDA | DKK 2.18B | DKK 1.98B | DKK 1.36B | DKK 909M | DKK 707M |
| Net income | DKK 1.36B | DKK 1.20B | DKK 815M | DKK 486M | DKK 335M |
| Free cash flow | DKK 1.90B | DKK 1.54B | DKK 953M | DKK 357M | DKK 118M |
| Capital expenditure | DKK 357M | DKK 360M | DKK 1.30B | DKK 379M | DKK 353M |
| Total debt | DKK 422M | DKK 418M | DKK 1.19B | DKK 765M | DKK 696M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| ALK-abello A/S ALK-B.CO | $8.14B | -5% | +17% | 27% | 35.7× | 7.6% |
| Allergy Therapeutics AGY.L | n/a | -87% | n/a | n/a | n/a | n/a |
| Merck & MRK | $362B | +33% | +5% | 18% | 17.4× | 4.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ALK-B.CO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.4% | +2.7% | 9th highest of 21 |
| 6-month return | -5.0% | +14.2% | 6th lowest of 21 |
| Distance from 52-week high | -10.5% | -16.5% | 10th highest of 21 |
| Revenue growth (TTM) | +16.5% | +12.8% | 10th highest of 21 |
| Operating margin | 26.7% | 13.8% | 2nd highest of 20 |
| Forward P/E | 35.7× | 23.4× | 4th most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 7.6% | 15.2% | 6th least demanding of 14 |
| Growth delivered (Del g) | +12.6% | +8.7% | 4th highest of 14 |
| Hurdle (Req g minus delivered) | -5.0 pp | -0.3 pp | 7th least demanding of 14 |
| ROIC minus cost of capital | +19.3 pp | +1.9 pp | 3rd highest of 18 |
| EV / EBITDA | 24.3× | 17.4× | 6th most expensive of 12 |
| Net debt / EBITDA | -0.6× | 0.8× | 5th least indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ALK-abello A/S ALK-B.CO | Denmark | $8.14B | -5% | +17% | 27% | 35.7× | 7.6% | +12.6% |
| Asymchem Laboratories (Tianjin) 6821.HK | Hong Kong | $8.19B | +22% | +24% | 17% | 29.2× | n/a | n/a |
| Kyowa Kirin 4151.T | Japan | $8.05B | +4% | +10% | 24% | 15.6× | -6.1% | +9.3% |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $8.02B | +47% | +9% | 27% | n/a | -9.1% | +6.6% |
| Shanghai Pharmaceuticals 601607.SS | China | $8.32B | -2% | +4% | 3% | 11.4× | -10.0% | +8.1% |
| Corcept Therapeutics CORT | United States | $7.96B | +39% | +30% | 12% | 16.4× | 24.9% | +16.6% |
| Rhythm Pharmaceuticals RYTM | United States | $7.78B | +19% | +61% | -67% | n/a | n/a | n/a |
| Protagonist Therapeutics PTGX | United States | $8.54B | +33% | +35% | 21% | 48.4× | 47.5% | +10.0% |
| Praxis Precision Medicines PRAX | United States | $7.75B | -16% | -100% | n/a | n/a | n/a | n/a |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.73B | +9% | +33% | 20% | 32.0× | 20.0% | +9.4% |
| Alkermes Public ALKS | United States | $7.71B | +31% | +15% | 5% | n/a | 31.5% | +7.3% |
| Shanghai Fosun Pharmaceutical (Group) 2196.HK | Hong Kong | $8.69B | -10% | +10% | 6% | 10.4× | 20.5% | +5.8% |
| Grifols GRF.MC | Spain | $7.49B | +23% | 0% | 16% | 13.0× | 6.8% | +7.1% |
| Cytokinetics CYTK | United States | $7.46B | -30% | -21% | -1,046% | n/a | n/a | n/a |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.37B | +60% | +58% | 14% | 61.7× | 9.9% | +45.5% |
| Bachem BANB.SW | Switzerland | $7.32B | +3% | +5% | 19% | 33.1× | n/a | n/a |
| Huadong Medicine 000963.SZ | China | $7.29B | -17% | +2% | 9% | 14.0× | -2.7% | +5.3% |
| ImmunityBio IBRX | United States | $9.15B | +1% | +193% | -152% | n/a | n/a | n/a |
| TG Therapeutics TGTX | United States | $9.16B | +40% | +76% | 17% | 30.9× | 50.3% | +426.7% |
| Madrigal Pharmaceuticals MDGL | United States | $9.28B | -22% | +93% | -11% | 79.5× | n/a | n/a |
| Amneal Pharmaceuticals AMRX | United States | $7.01B | +53% | +9% | 17% | 17.7× | 15.2% | +8.7% |